Economics of the Recombinant Human Granulocyte Colony-Stimulating Factors

[1]  J. Armitage,et al.  Myeloid growth factors. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  M. Esser,et al.  Economic evaluations of granulocyte colony-stimulating factor , 2012, PharmacoEconomics.

[3]  G. Lyman,et al.  Therapeutic Use of Granulocyte Colony-Stimulating Factors for Established Febrile Neutropenia , 2012, PharmacoEconomics.

[4]  G. Lyman,et al.  Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. , 2007, Cancer treatment and research.

[5]  W. Jelkmann.  Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences , 2010, American journal of hematology.

[6]  A. Škrlin,et al.  Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. , 2010, Biologicals : journal of the International Association of Biological Standardization.

[7]  H. Mellstedt.  Implications of the development of biosimilars for cancer treatment. , 2010, Future oncology.

[8]  G. Lyman,et al.  Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Bronchud,et al.  Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial , 2010, Annals of Hematology.

[10]  C. Earle,et al.  When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. , 2009, Journal of the National Cancer Institute.

[11]  Q. Doan,et al.  The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK , 2009 .

[12]  G. Lyman,et al.  Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. , 2009, Clinical therapeutics.

[13]  S. Ramsey,et al.  Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  G. Lyman,et al.  Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States , 2009 .

[15]  E. Feuer,et al.  Estimates and projections of value of life lost from cancer deaths in the United States. , 2008, Journal of the National Cancer Institute.

[16]  G. Lyman,et al.  Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  G. Lyman,et al.  Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  E. Adang,et al.  Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Niederwieser,et al.  The challenge of biosimilars. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  G. Lyman,et al.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Bennett,et al.  Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. , 2007, The oncologist.

[22]  N. Kearney,et al.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. , 2006, European journal of cancer.

[23]  E. Adang,et al.  Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Lyman,et al.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients , 2006, Cancer.

[26]  E. Adang,et al.  Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Lyman.  Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[28]  B. Wiens,et al.  First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Friedberg,et al.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Rapoport,et al.  Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score , 2004, Supportive Care in Cancer.

[31]  G. Lyman,et al.  Effects of Indirect and Additional Direct Costs on the Risk Threshold for Prophylaxis with Colony‐Stimulating Factors in Patients at Risk for Severe Neutropenia from Cancer Chemotherapy , 2004, Pharmacotherapy.

[32]  L. Elting,et al.  The economic burden of supportive care of cancer patients , 2004, Supportive Care in Cancer.

[33]  G. Lyman,et al.  Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Lyman,et al.  Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP‐R, or CNOP chemotherapy for intermediate‐grade non‐Hodgkin lymphoma , 2003, Cancer.

[35]  G. Lyman,et al.  The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study , 2003, BMC nursing.

[36]  J. Armitage,et al.  2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L. Elting,et al.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Lyman,et al.  The economics of febrile neutropenia: implications for the use of colony-stimulating factors. , 1998, European journal of cancer.

[39]  Thomas J. Smith,et al.  Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Finberg,et al.  Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[42]  Josef Korinek,et al.  Proceedings of the American Society of Clinical Oncology , 1982 .